CGT

97개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved97 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleCabaletta BioPhase 2

CABA-201 (CABA-201)

Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS) · Pemphigus Vulgaris

#PemphigusVulgaris#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Recruiting
CGTLimited DatastalePolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 4Status Recruiting
CGTLimited DatastaleSanofiPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 2

Arlocabtagene Autoleucel (Arlocabtagene Autoleucel)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleNovatim Immune Therapeutics (Zh…Phase 2

KQ-2003 CAR T-cells (KQ-2003 CAR T-cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-AIO T cells (LCAR-AIO T cells)

Multiple Sclerosis (MS); Neuromyelitis Optica Spectrum Disease (NMOSD) · Systemic Lupus Erythematosus (SLE)

#SystemicLupusErythematosusSLE#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Discontinued
CGTLimited DatastaleYake Biotechnology Ltd.Phase 2

BCMA CAR-T cells (BCMA CAR-T cells)

Multiple Myeloma; New Diagnosis Tumor · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
CGTLimited DatastaleMillennium Pharmaceuticals, Inc.Phase 2

ENK Cell Infusion (ENK Cell Infusion)

Asymptomatic Multiple Myeloma · Asymptomatic Multiple Myeloma

#AsymptomaticMultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 2Status Active
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

2 / 5 pages

← PreviousNext →